Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 15, Issue 10, Pages 1301-1312
Publisher
Informa UK Limited
Online
2016-07-29
DOI
10.1080/14740338.2016.1217989
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone
- (2015) Diogo Mendes et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Drug-safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting risks earlier
- (2014) Carlos Alves et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Balancing benefit and risk of medicines: a systematic review and classification of available methodologies
- (2014) Shahrul Mt-Isa et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Impact of Inclusion of Industry Trial Results Registries as an Information Source for Systematic Reviews
- (2014) Regine Potthast et al. PLoS One
- Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study
- (2014) S. Hughes et al. BMJ Open
- Quality of reporting in systematic reviews of adverse events: systematic review
- (2014) L. Zorzela et al. BMJ-British Medical Journal
- A Primer on Effectiveness and Efficacy Trials
- (2014) Amit G Singal et al. Clinical and Translational Gastroenterology
- The Future of Population-Based Postmarket Drug Risk Assessment: A Regulator’s Perspective
- (2013) T A Hammad et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Sources of information used by regulatory agencies on the generation of drug safety alerts
- (2013) Carlos Alves et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed
- (2013) L. Citrome et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Pooled Risk Estimates for Adverse Effects from Different Observational Study Designs: Methodological Overview
- (2013) Su Golder et al. PLoS One
- Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports
- (2013) Peter Doshi et al. BMJ Open
- Echocardiographic Evidence for Valvular Toxicity of Benfluorex: A Double-Blind Randomised Trial in Patients with Type 2 Diabetes Mellitus
- (2012) Geneviève Derumeaux et al. PLoS One
- Drug safety assessment in clinical trials: methodological challenges and opportunities
- (2012) Sonal Singh et al. Trials
- Data sources on drug safety evaluation: a review of recent published meta-analyses
- (2011) Carlos Alves et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Rosiglitazone Revisited
- (2010) Steven E. Nissen et al. ARCHIVES OF INTERNAL MEDICINE
- The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database
- (2010) Najat Ziyadeh et al. CLINICAL THERAPEUTICS
- Rosiglitazone: a European regulatory perspective
- (2010) E. Blind et al. DIABETOLOGIA
- Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
- (2010) David J. Graham et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus
- (2010) Alain Weill et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Relative vs. absolute measures of benefit and risk: whatâs the difference?
- (2009) L. Citrome ACTA PSYCHIATRICA SCANDINAVICA
- Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease
- (2009) Darbie Maccubbin et al. AMERICAN JOURNAL OF CARDIOLOGY
- Communicating benefit and risk
- (2009) Trevor Baglin BRITISH JOURNAL OF HAEMATOLOGY
- Rapid Identification of Myocardial Infarction Risk Associated With Diabetes Medications Using Electronic Medical Records
- (2009) J. S. Brownstein et al. DIABETES CARE
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- (2009) Philip D Home et al. LANCET
- Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy
- (2008) Wolfgang C. Winkelmayer et al. ARCHIVES OF INTERNAL MEDICINE
- Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?
- (2008) Su Golder et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
- (2008) D. Maccubbin et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Benefits and Risks of Drug Treatments
- (2008) Jan P. Vandenbroucke et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007
- (2008) Alexander M. Walker et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran
- (2008) G. Agnelli et al. THROMBOSIS RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started